Docter, a Taiwanese non-invasive blood glucose watch developer, agreed to go public via SPAC merger with Aimfinity Investment, a Cayman Islands incorporated special purpose acquisition company, in a $60m deal. “Docter Inc. is committed to pushing the boundaries of what wearable devices can achieve in the realm of health and well-being. Our team is confident that, with the support of Aimfinity Investment. I, we can continue to innovate and bring our revolutionary wearable technologies to a broader audience as a publicly traded company. We are thrilled to have found such outstanding partners as we embark on this new phase of our journey,” Hsin-Ming Huang, Docter CEO.